Search Results
(
)
Filter by
Filter by health areas, people and populations, or solutions
Filter by EGPAF’s stories, research, resources or news
Journal Articles
Examining teen club attendance and viral load suppression among adolescents under differentiated HIV care in Malawi
Published January 5, 2025
Background In Malawi, compared to adults, adolescents have higher rates of high HIV viremia and poorer antiretroviral therapy (ART) outcomes. The Ministry of Health, supported by the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), implemented the provision of differentiated care clubs for adolescents living with HIV (ALHIV), called “teen clubs,” to…
Topics:
Adolescents
Countries:
Malawi
Journal Articles
Improving HIV testing and retention among adolescents and youths
Published December 19, 2024
Adolescents and youth living with HIV (AYLHIV) often face significant challenges in HIV care. Elizabeth Glaser Pediatric AIDS Foundation in Malawi implemented the Red-Carpet Program (RCP) to provide fast-tracked services for AYLHIV in care.This study aimed to assess the effect of RCP on Provider-Initiated HIV testing, linkage to care and…
Topics:
Adolescents
Countries:
Malawi
Program Tools
Breakthrough Champion Advocacy Toolkit
Published December 1, 2024
This Breakthrough Champion Advocacy Toolkit is targeted towards strengthening the capacity of adolescents and youth to advocate for addressing HIV treatment inequalities to end AIDS. The Toolkit serves as a training manual for the Breakthrough Partnership’s adolescent champions to develop advocacy skills and gain knowledge about HIV treatment gaps and…
Topics:
Adolescents
Countries:
Mozambique,
Nigeria,
Uganda
Journal Articles
Follow-Up Outcomes of Children, Adolescents, and Young People on Darunavir-Based Third-Line Antiretroviral Therapy
Published October 30, 2024
Background: We assessed clinical outcomes among children, adolescents, and people younger than 25 years on darunavir-based antiretroviral therapy (ART) in 9 sub-Saharan African countries. Setting: Third-line ART centers in Cameroon, Eswatini, Kenya, Lesotho, Nigeria, Rwanda, Uganda, Zambia, and Zimbabwe. Methods: From January 2019 to December 2022, we collected data from a cohort of…
Topics:
Adolescents,
Pediatric HIV
Countries:
Cameroon,
Eswatini,
Kenya,
Lesotho,
Nigeria,
Rwanda,
Uganda,
Zambia,
Zimbabwe
Issue Briefs
Building Trust for Global Health
Published October 2, 2024
Most causes of deaths in children could be prevented with effective treatment and interventions that are feasible for implementation, even in resource-constrained settings. However, appropriate medicines to save and improve the lives of infants and children often do not exist, are unavailable, or are not quality assured. This puts children’s…
Topics:
HIV,
Pediatric HIV
Issue Briefs
Building a Future of Health
Published October 2, 2024
An Unspoken Crisis: Children Are Being Left Behind In 2022, one child died every six seconds. The causes of most of those deaths were preventable. This is unacceptable. Whereas countries have the tools and knowledge to end preventable deaths and suffering in children, children face inequalities in access to health…
Topics:
Pediatric HIV,
Tuberculosis (TB)
Resource
Looking Forward
Published September 15, 2024
Topics:
Adolescents,
Pediatric HIV,
Prevention of Mother-to-Child Transmission (PMTCT)
Journal Articles
The Rollout of Paediatric Dolutegravir and Virological Outcomes Among Children Living with HIV in Mozambique
Published July 30, 2024
Background In 2022, Mozambique introduced Dolutegravir 10mg (pDTG), as part of paediatric antiretroviral therapy for children weighing < 20 kg. Understanding real-world challenges during national rollout can strengthen health systems in resource-limited settings. Objectives We described the transition rate to, and new initiation of, pDTG, viral load suppression (VLS)…
Topics:
Pediatric HIV,
Research
Countries:
Mozambique
Journal Articles
Adolescents and Young Adults with HIV and Unsuppressed Viral Load
Published July 29, 2024
Purpose of review Adolescents and youth living with HIV (AYLHIV) have worse outcomes at all stages of the care cascade when compared with adults, yet adolescents and youth with unsuppressed viral load are typically excluded from phase 3 studies of novel HIV therapeutic agents and emerging strategies. Long-acting agents…
Topics:
Adolescents